Granules India Limited — Updates, 21-02-2025: Press Release

Granules India has signed an acquisition agreement for Senn Chemicals AG, a Swiss-based CDMO specializing in peptide manufacturing. This strategic move allows Granules to enter the high-growth peptide segment and enhances its capabilities in contract research, development, and manufacturing services. The acquisition, expected to close in the first half of 2025, will integrate Senn’s expertise in Liquid-Phase and Solid-Phase Peptide Synthesis, bolstering Granules' position in the rapidly expanding peptide-based therapeutics market, including applications in anti-diabetic and anti-obesity treatments.

The partnership is poised to enhance Granules' CDMO business, leveraging Senn's established customer relationships in the pharmaceutical, cosmetics, and theragnostic sectors. This acquisition is seen as a pivotal moment for Granules, aligning with its vision to foster innovation and affordability while expanding its footprint in the global market. The collaboration is expected to accelerate the growth of peptide-based applications, reinforcing Granules' commitment to becoming a leading provider of complex therapeutics.